Inodilators in nitric oxide resistant persistent pulmonary hypertension of the newborn*

Pediatric Critical Care Medicine

Volumn 14, Issue 1, 2013, Pages 107-109

  Lakshminrusimha, Satyan ^a   Steinhorn, Robin H ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

cyclic AMP; hypoxic respiratory failure; phosphodiesterase; pulmonary vasculature; vasodilation

Indexed keywords

CYCLIC AMP; CYCLIC GMP; MILRINONE; NITRIC OXIDE; PHOSPHODIESTERASE III;

CONGESTIVE HEART FAILURE; DRUG CLEARANCE; DRUG HALF LIFE; EDITORIAL; HUMAN; INTENSIVE CARE; LUNG BLOOD VESSEL; LUNG VASOCONSTRICTION; NEWBORN DISEASE; NONHUMAN; PEDIATRICS; PERSISTENT PULMONARY HYPERTENSION; PRIORITY JOURNAL; VASODILATATION;

HUMANS; HYPERTENSION, PULMONARY; MILRINONE; PHOSPHODIESTERASE 3 INHIBITORS;

EID: 84873192867     PISSN: 15297535     EISSN: 19473893     Source Type: Journal    
DOI: 10.1097/PCC.0b013e318250af44     Document Type: Editorial

References (25)

1. Steinhorn RH: Neonatal pulmonary hypertension. Pediatr Crit Care Med 2010; 11(2 Suppl):S79-S84
2. Inhaled nitric oxide in full-Term and nearly full-Term infants with hypoxic respiratory failure. The Neonatal Inhaled Nitric Oxide Study Group. N Engl J Med 1997;336:597-604
3. Clark RH, Kueser TJ, Walker MW, et al: Low-Dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. N Engl J Med 2000; 342:469-474
4. Davidson D, Barefield ES, Kattwinkel J, et al: Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: A randomized, double-masked, placebo-controlled, dose-response, multicenter study. The I-NO/PPHN Study Group. Pediat¬rics 1998; 101:325-334
5. Roberts JD Jr, Fineman JR, Morin FC 3rd, et al: Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group. N Engl J Med 1997; 336:605-610
6. Lakshminrusimha S, Russell JA, Wedgwood S, et al: Superoxide dis¬mutase improves oxygenation and reduces oxidation in neonatal pulmo¬nary hypertension. Am J Respir Crit Care Med 2006; 174:1370-1377
7. Lakshminrusimha S, Russell JA, Steinhorn RH, et al: Pulmonary arterial contractility in neonatal lambs increases with 100% oxygen resuscita¬tion. Pediatr Res 2006; 59:137-141
8. Lakshminrusimha S, Steinhorn RH, Wedgwood S, et al: Pulmonary hemodynamics and vascular reactivity in asphyxiated term lambs resuscitated with 21 and 100% oxygen. J Appl Physiol 2011; 111: 1441-1447
9. Farrow KN, Groh BS, Schumacker PT, et al: Hyperoxia increases phos¬phodiesterase 5 expression and activity in ovine fetal pulmonary artery smooth muscle cells. Circ Res 2008; 102:226-233
10. Murray F, MacLean MR, Pyne NJ: Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension. Br J Pharmacol 2002; 137:1187-1194
11. Chen B, Lakshminrusimha S, Czech L, et al: Regulation of phosphodies¬terase 3 in the pulmonary arteries during the perinatal period in sheep. Pediatr Res 2009; 66:682-687
12. Thelitz S, Oishi P, Sanchez LS, et al: Phosphodiesterase-3 inhibition pre¬vents the increase in pulmonary vascular resistance following inhaled ni¬tric oxide withdrawal in lambs. Pediatr Crit Care Med 2004; 5:234-239
13. Opie LH: "Inodilators". Lancet 1986; 1:1336
14. Bailey JM, Hoffman TM, Wessel DL, et al: A population pharmacokinetic analysis of milrinone in pediatric patients after cardiac surgery. J Phar¬macokinet Pharmacodyn 2004; 31:43-59
15. Chang AC, Atz AM, Wernovsky G, et al: Milrinone: Systemic and pulmo¬nary hemodynamic effects in neonates after cardiac surgery. Crit Care Med 1995; 23:1907-1914
16. Hoffman TM, Wernovsky G, Atz AM, et al: Prophylactic intravenous use of milrinone after cardiac operation in pediatrics (PRIMACORP) study. Prophylactic Intravenous Use of Milrinone After Cardiac Operation in Pediatrics. Am Heart J 2002; 143:15-21
17. Hoffman TM, Wernovsky G, Atz AM, et al: Efficacy and safety of mil¬rinone in preventing low cardiac output syndrome in infants and chil¬dren after corrective surgery for congenital heart disease. Circulation 2003; 107:996-1002
18. Lakshminrusimha S, Porta NF, Farrow KN, et al: Milrinone enhances re¬laxation to prostacyclin and iloprost in pulmonary arteries isolated from lambs with persistent pulmonary hypertension of the newborn. Pediatr Crit Care Med 2009; 10:106-112
19. Rashid N, Morin FC 3rd, Swartz DD, et al: Effects of prostacyclin and milrinone on pulmonary hemodynamics in newborn lambs with persis¬tent pulmonary hypertension induced by ductal ligation. Pediatr Res 2006; 60:624-629
20. Lindsay CA, Barton P, Lawless S, et al: Pharmacokinetics and pharma¬codynamics of milrinone lactate in pediatric patients with septic shock. J Pediatr 1998; 132:329-334
21. Paradisis M, Evans N, Kluckow M, et al: Pilot study of milrinone for low systemic blood flow in very preterm infants. J Pediatr 2006; 148: 306-313
22. Paradisis M, Jiang X, McLachlan AJ, et al: Population pharmacokinet¬ics and dosing regimen design of milrinone in preterm infants. Arch Dis Child Fetal Neonatal Ed 2007; 92:F204-F209
23. McNamara PJ, Laique F, Muang-In S, et al: Milrinone improves oxygenation in neonates with severe persistent pulmonary hypertension of the newborn. J Crit Care 2006; 21:217-222
24. McNamara PJ, Shivananda SP, Sahni M, et al: Pharmacology of Mil¬rinone in Neonates With Persistent Pulmonary Hypertension of the Newborn and Suboptimal Response to Inhaled Nitric Oxide. Pediatr Crit Care Med 2013; 14:74-84
25. Stroshane RM, Koss RF, Biddlecome CE, et al: Oral and intravenous pharmacokinetics of milrinone in human volunteers. J Pharm Sci 1984; 73:1438-1441